17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 381-388

  Gossett, Dana R ^a   Bradley, Megan S ^a   Jin, Xiaohong ^a   Lin, Jiayuh ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

17 AAG; 17 DMAG; AKT; Endometrial cancer; HSP90; Molecular therapeutics

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 N,N DIMETHYLETHYLENE DIAMINE GELDANAMYCIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYTOTOXIC AGENT; HEAT SHOCK PROTEIN 90; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; GENITAL NEOPLASMS, FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINONES; RIFABUTIN;

EID: 12344327270     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.10.009     Document Type: Article

References (46)

1. B. Druker, and N. Lydon Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia J. Clin. Invest. 105 1 2000 3 7
2. B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, and J. Ford Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 14 2001 1031 1037
3. M. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P. Rao Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification Science 293 5531 2001 876 880
4. J. Isaacs, W. Xu, and L. Neckers Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 3 3 2003 213 217
5. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol. Med. 8 2002 S55 61
6. M. Blagosklonny Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs Leukemia 16 4 2002 455 462
7. M. Ferrarini, S. Heltai, M. Zocchi, and C. Rugarli Unusual expression and localization of heat-shock proteins in human tumor cells Int. J. Cancer 51 4 1992 613 619
8. S. Sato, N. Fujita, and T. Tsuruo Modulation of Akt kinase activity by binding to Hsp90 Proc. Natl. Acad. Sci. U. S. A. 97 2000 10832 10837
9. D. Solit, A. Basso, A. Olshe, H. Scher, and N. Rosen Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol Cancer Res. 63 9 2003 2139 2144
10. K. Bisht, C. Bradbury, D. Mattson, A. Kaushal, A. Sowers, and S. Markovina Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity Cancer Res. 63 24 2003 8984 8995
11. D. Solit, F. Zheng, M. Drobnjak, P. Munster, B. Higgins, and D. Verbel 17-Allylamino-17demethoxygeldanamycin induces the degradation of androgen receptor and HER2/neu and inhibits the growth of prostate cancer xenografts Clin. Cancer Res. 8 5 2002 986 993
12. R. Nimmanapalli, E. O'Bryan, and K. Bhalla Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts Cancer Res. 61 5 2001 1799 1804
13. Y. Nagata, T. Anan, T. Yoshida, T. Mizukami, Y. Taya, and T. Fujiwara The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association Oncogene 18 44 1999 6037 6049
14. M. Blagosklonny, J. Toretsky, S. Bohen, and L. Neckers Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 Proc. Natl. Acad. Sci. U. S. A. 93 16 1996 8379 8383
15. J. Jez, J. Chen, G. Rastelli, R. Stroud, and D. Santi Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90 Chem. Biol. 10 4 2003 361 368
16. V. Smith, E. Sausville, R. Camlier, H. Fiebig, and A. Burger 17-DMAG (NSC 707545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG Eur. J. Cancer 38 S7 2002 S60
17. K. Wataba, T. Satio, K. Fukunaka, K. Ashihara, M. Nishimura, and R. Kudo Over-expression of heat shock proteins in carcinogenic endometrium Int. J. Cancer 91 4 2001 448 456
18. K. Nanbu, I. Konishi, T. Komatsu, M. Mandai, S. Yamamoto, and H. Kuroda Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression Cancer 77 2 1996 330 338
19. L. Luo, I. Herrera, A. Soosaipillai, and E. Diamandis Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library Br. J. Cancer 87 3 2002 339 343
20. L. Vargas-Roig, F. Gago, O. Tello, J. Aznar, and D. Ciocca Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy Int. J. Cancer 79 5 1998 468 475
21. S. Sato, N. Fujita, and T. Tsuruo Modulation of Akt kinase activity by binding to Hsp90 Proc. Natl. Acad. Sci. U. S. A. 97 20 2000 10832 10837
22. G. Kulik, A. Klippel, and M.J. Weber Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt Mol. Cell. Biol. 17 1997 1595 1606
23. T. Franke, D. Kaplan, and L. Cantley PI3K: downstream AKTion blocks apoptosis Cell 88 1997 435 437
24. H. Tashiro, M. Blazes, R. Wu, K. Cho, S. Bose, and S. Wang Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies Cancer Res. 57 1997 3935 3940
25. I. Ali Gatekeeper for endometrium: the PTEN tumor suppressor gene J. Natl. Cancer Inst. 92 2000 861 863
26. S. Bose, A. Crane, H. Hibshoosh, M. Mansukhani, and L.R.P. Sandweis Reduced expression of PTEN correlates with breast cancer progression Hum. Pathol. 33 4 2002 405 409
27. D. Freihoff, A. Kempe, B. Beste, B. Wappenschmidt, E. Kreyer, and Y. Hayashi Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas Br. J. Cancer 79 5/6 1999 754 758
28. N. Nassif, G. Lobo, X. Wu, C. Henderson, C. Morrison, and C. Eng PTEN mutations are common in sporadic microsatellite stable colorectal cancer Oncogene 23 2 2004 617 628
29. V. Stambolic, A. Suzuki, J. de la Pompa, G. Brothers, C. Mirtsos, and T. Sasaki Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 95 1998 29 39
30. Y. Kanamori, J. Kigawa, H. Itamochi, M. Shimada, M. Takahashi, and S. Kamazawa Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin. Cancer Res. 7 2001 892 895
31. A. Bellacosa, D. de Feo, A. Godwin, D. Bell, J. Cheng, and D. Altomare Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
32. J. Cheng, A. Godwin, A. Bellacosa, T. Taguchi, T. Franke, and T. Hamilton AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proc. Natl. Acad. Sci. U. S. A. 89 1992 9267 9271
33. T. Franke, S. Yang, T. Chan, K. Datta, A. Kazlauskas, and D. Morrison The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase Cell 81 1995 727 736
34. N. Fujita, S. Sato, A. Ishida, and T. Tsuruo Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase 1 J. Biol. Chem. 277 12 2002 10346 10353
35. C. Holinka, H. Hata, H. Kuramoto, and E. Gurpide Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line) Cancer Res. 46 1986 2771 2774
36. V. Bae-Jump, E. Segreti, D. Vandermolen, and S. Kauma Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro Gynecol. Oncol. 73 2 1999 265 272
37. A. Basso, D. Solit, P. Munster, and N. Rosen Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 Oncogene 21 8 2002 1159 1166
38. R. Bagatell, O. Khan, G. Paine-Murrieta, C.W. Taylor, and S.L.W. Akinaga Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer Clin. Cancer Res. 7 7 2001 2076 2084
39. G. Richardson, G. Dickersin, L. Atkins, D. MacLaughlin, S. Raam, and L. Merk KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer Gynecol. Oncol. 17 2 1984 213 230
40. C. Ferlini, G. Scambia, M. Marone, M. Distefano, C. Gaggini, and G. Ferrandina Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines Br. J. Cancer 79 2 1999 257 263
41. N. Sladek Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5′-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent Chem.-Biol. Interact. 143-144 2003 63 74
42. D. Chen, M. Qi, K. Auborn, and T. Carter Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium J. Nutr. 131 12 2001 3294 3302
43. E. Castro-Rivera, and S. Safe Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture J. Steroid Biochem. Mol. Biol. 64 5-6 1998 287 295
44. D. Way, D. Grosso, J. Davis, E. Surwit, and C. Christian Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture In Vitro 19 3 Pt 1 1983 147 158
45. M. Nishida The Ishikawa cells from birth to the present Hum. Cell 15 3 2002 104 117
46. G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell, and L. Neckers 17AAG: low target binding affinity and potent cell activity-Finding an explanation Mol. Cancer Ther. 2 2 2003 123 129